Comparison of Pharmacokinetic Characteristics and Safety Between JW Amlodipine(R) Tablet 5 mg and Novarsc(R) Tablet 5 mg in Healthy Male Volunteers
Journal of Korean Society for Clinical Pharmacology and Therapeutics
;
: 95-103, 2013.
Article
in Korean
| WPRIM
| ID: wpr-30069
ABSTRACT
BACKGROUND:
Amlodipine is a third-generation dihydropyridine calcium channel blocker, which has proven to be a useful drug against hypertension or angina.METHODS:
This randomized, open-label, two-period, two-treatment, single-dose, crossover study was conducted in twenty healthy male volunteers. Subjects were administered 5 mg of the test or reference formulation. After 2-week washout period, the other formulation was administered. Blood samples were collected up to 144 hours after drug administration, and plasma amlodipine concentrations were determined by validated liquid chromatography-tandem mass spectrometry. Drug safety was assessed using measurement of vital signs, physical examinations, laboratory test, electrocardiograms, and adverse event monitoring.RESULTS:
All subjects were completed this study. The geometric mean ratios of Cmax and AUClast were 1.078 (90 % CI, 0.968 - 1.200) and 1.095 (90 % CI, 1.011 - 1.186), respectively. There were no serious adverse events were reported by both formulations.CONCLUSION:
This study showed the test and reference formulations had similar pharmacokinetics and safety profiles.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Physical Examination
/
Plasma
/
Mass Spectrometry
/
Pharmacokinetics
/
Calcium Channels
/
Amlodipine
/
Cross-Over Studies
/
Electrocardiography
/
Vital Signs
/
Healthy Volunteers
Type of study:
Controlled clinical trial
Limits:
Humans
/
Male
Language:
Korean
Journal:
Journal of Korean Society for Clinical Pharmacology and Therapeutics
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS